MERCURY BIO Trademark

Trademark Overview


On Friday, June 14, 2024, a trademark application was filed for MERCURY BIO with the United States Patent and Trademark Office. The USPTO has given the MERCURY BIO trademark a serial number of 98602178. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Friday, June 14, 2024. This trademark is owned by Mercury Bio, Inc.. The MERCURY BIO trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development in the fields of pharmaceuticals, therapeutics, and biologics, namely, yeast derived extracellular vesicle-based delivery systems for pharmaceuticals, therapeutics, and biologics; Research and development in the fields of pharmaceuticals, therapeutics, and biologics, namely, development of humanized yeast extracellular vesicles delivery systems for pharmaceuticals, therapeutics, and biologics; Medical research and development in the field of molecular biology, genetic engineering, drug delivery, and bioinformatics; Medical research and development in the field of molecular biology, genetic engineering, drug delivery, and bioinformatics, namely genetically engineering yeast cells to produce extracellular vesicles for delivery of pharmaceuticals, therapeutics, and biologics; Bioinformatics, namely genetically engineering yeast cells to produce humanized extracellular vesicles delivery of for pharmaceuticals, therapeutics, and biologics; Research and development o...

General Information


Serial Number98602178
Word MarkMERCURY BIO
Filing DateFriday, June 14, 2024
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateFriday, June 14, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesResearch and development in the fields of pharmaceuticals, therapeutics, and biologics, namely, yeast derived extracellular vesicle-based delivery systems for pharmaceuticals, therapeutics, and biologics; Research and development in the fields of pharmaceuticals, therapeutics, and biologics, namely, development of humanized yeast extracellular vesicles delivery systems for pharmaceuticals, therapeutics, and biologics; Medical research and development in the field of molecular biology, genetic engineering, drug delivery, and bioinformatics; Medical research and development in the field of molecular biology, genetic engineering, drug delivery, and bioinformatics, namely genetically engineering yeast cells to produce extracellular vesicles for delivery of pharmaceuticals, therapeutics, and biologics; Bioinformatics, namely genetically engineering yeast cells to produce humanized extracellular vesicles delivery of for pharmaceuticals, therapeutics, and biologics; Research and development of delivery systems for therapeutic compounds, namely, yeast-derived extracellular vesicle-based drug delivery systems for therapeutic compounds for the treatment of viral pathogens, cancer and inherited disorder in humans; Research and development of delivery systems for therapeutic compounds, namely, yeast-derived extracellular vesicle-based drug delivery of therapeutic compounds; Research and development of delivery systems for therapeutic nucleic acids, namely, yeast-derived extracellular vesicle-based drug delivery of therapeutic nucleic acids, namely, RNA; Research and development of delivery systems for therapeutic peptides, namely, yeast-derived extracellular vesicle-based drug delivery of therapeutic peptides; Research and development of delivery systems for gene-editing proteins, namely, yeast-derived extracellular vesicle-based drug delivery of gene-editing proteins; Research and development of delivery systems for vaccines, namely, yeast-derived extracellular vesicle-based drug delivery systems for vaccines; Research and development of delivery systems for vaccines, namely, yeast-derived extracellular vesicle-based drug delivery systems for pharmaceutical compounds; Research and development of the production of extracellular vesicles for therapeutic uses, namely, yeast-derived extracellular vesicles for therapeutic uses; Research and development of new biological products for therapeutic use; Design and development of nucleic acids, proteins, enzymes, and drug compounds for use in pharmaceuticals, biotechnology, medical, and diagnostic applications; and Design and development of loading systems to load nucleic acids, proteins, enzymes, and drug compounds into yeast-derived extracellular vesicles for therapeutic uses

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, June 14, 2024
Primary Code042
First Use Anywhere DateTuesday, January 17, 2023
First Use In Commerce DateTuesday, January 17, 2023

Trademark Owner History


Party NameMercury Bio, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSanta Fe, NM 87507

Trademark Events


Event DateEvent Description
Friday, June 14, 2024NEW APPLICATION ENTERED
Friday, June 14, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED